Document Classification

Section Type: RESULTS

Text: After 26 weeks, patients treated with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, and 40 mg weekly had significantly better response rates than those treated with placebo : ACR20 (35. 8 %, 39. 3 %, 46. 0 %, 53. 4 %, respectively v 19. 1 % ; p < or = 0. 01) ; ACR50 (18. 9 %, 20. 5 %, 22. 1 %, 35. 0 % v 8. 2 % ; p < or = 0. 05) ; ACR70 (8. 5 %, 9. 8 %, 12. 4 %, 18. 4 % v 1. 8 % ; p < or = 0. 05).